FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:2725-2726 June 22, 2006 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Park-Wyllie, L. Y. PubMed Citation

To the Editor: Park-Wyllie and colleagues (March 30 issue)¹ advise avoiding the use of gatifloxacin because of the increased risk of dysglycemia, and they suggest using alternative antibiotics, including other fluoroquinolones, that confer little or no increased risk of dysglycemia. This suggestion must be questioned. Although it appears that the administration of moxifloxacin has no clinically relevant effect on blood glucose homeostasis,² other fluoroquinolones may trigger dysglycemic events, especially in patients with diabetes who receive sulfonylureas.³ Clinicians should be aware of the possibility of dysglycemic events in patients receiving fluoroquinolones.

Karl P. Ittner, M.D., D.E.A.A.
University of Regensburg
D-93042 Regensburg, . . . [Full Text of this Article]

This article has been cited by other articles:

• Chacon-Moreno, B. E., Welsh, O., Cavazos-Rocha, N., de la Luz Salazar-Cavazos, M., Garza-Lozano, H. G., Said-Fernandez, S., Ocampo-Candiani, J., Vera-Cabrera, L. (2009). Efficacy of Ciprofloxacin and Moxifloxacin against Nocardia brasiliensis In Vitro and in an Experimental Model of Actinomycetoma in BALB/c Mice. Antimicrob. Agents Chemother. 53: 295-297 [Abstract] [Full Text]